Tags

Type your tag names separated by a space and hit enter

Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.
Transplant Proc. 2009 Jul-Aug; 41(6 Suppl):S3-5.TP

Abstract

Persistence of left ventricular hypertrophy (LVH) following renal transplantation is associated with unfavorable outcomes in renal transplant recipients. This review presents clinical data on LVH after renal transplantation and the role of antihypertensive therapy, especially ACE inhibitors, to reduce left ventricular mass, as well as the effects of interactions between antihypertensive medications acting on the renin-angiotensin system and immunosuppressive agents to regress LVH among renal transplant recipients. The effectiveness of sirolimus (SRL) to reduce posttransplantation LVH is also discussed in light of both animal model studies and 2 clinical trials in transplant recipients that showed the efficacy of this immunosuppressive agent to treat LVH in both kidney and heart transplant recipients.

Authors+Show Affiliations

Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria San Martino, Genova, Italy. ernesto.paoletti@hsanmartino.itNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19651293

Citation

Paoletti, E, and G Cannella. "Reducing the Risk of Left Ventricular Hypertrophy in Kidney Transplant Recipients: the Potential Role of Mammalian Target of Rapamycin." Transplantation Proceedings, vol. 41, no. 6 Suppl, 2009, pp. S3-5.
Paoletti E, Cannella G. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. Transplant Proc. 2009;41(6 Suppl):S3-5.
Paoletti, E., & Cannella, G. (2009). Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. Transplantation Proceedings, 41(6 Suppl), S3-5. https://doi.org/10.1016/j.transproceed.2009.06.091
Paoletti E, Cannella G. Reducing the Risk of Left Ventricular Hypertrophy in Kidney Transplant Recipients: the Potential Role of Mammalian Target of Rapamycin. Transplant Proc. 2009 Jul-Aug;41(6 Suppl):S3-5. PubMed PMID: 19651293.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. AU - Paoletti,E, AU - Cannella,G, Y1 - 2009/07/10/ PY - 2009/8/5/entrez PY - 2009/8/11/pubmed PY - 2010/1/9/medline SP - S3 EP - 5 JF - Transplantation proceedings JO - Transplant Proc VL - 41 IS - 6 Suppl N2 - Persistence of left ventricular hypertrophy (LVH) following renal transplantation is associated with unfavorable outcomes in renal transplant recipients. This review presents clinical data on LVH after renal transplantation and the role of antihypertensive therapy, especially ACE inhibitors, to reduce left ventricular mass, as well as the effects of interactions between antihypertensive medications acting on the renin-angiotensin system and immunosuppressive agents to regress LVH among renal transplant recipients. The effectiveness of sirolimus (SRL) to reduce posttransplantation LVH is also discussed in light of both animal model studies and 2 clinical trials in transplant recipients that showed the efficacy of this immunosuppressive agent to treat LVH in both kidney and heart transplant recipients. SN - 1873-2623 UR - https://www.unboundmedicine.com/medline/citation/19651293/Reducing_the_risk_of_left_ventricular_hypertrophy_in_kidney_transplant_recipients:_the_potential_role_of_mammalian_target_of_rapamycin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(09)00823-9 DB - PRIME DP - Unbound Medicine ER -